SCTB-35

N/A

Report date: 2026/05/28 20:00:21

Base Information

Drug NameSCTB-35
Drug Alias NameSCTB35SCTB-35
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitorsT cell surface glycoprotein CD3 inhibitors
TargetsB-lymphocyte antigen CD20T cell surface glycoprotein CD3
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLymphoma, Follicular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSinoCelltech Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLymphoma, Follicular +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A